Compare CHOW & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | PRQR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Hong Kong | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.1M | 250.7M |
| IPO Year | 2025 | 2014 |
| Metric | CHOW | PRQR |
|---|---|---|
| Price | $0.76 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | ★ 2.5M | 558.5K |
| Earning Date | 12-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $23,409,092.00 | $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.27 | ★ N/A |
| Revenue Growth | ★ 28.62 | N/A |
| 52 Week Low | $0.65 | $1.07 |
| 52 Week High | $21.91 | $3.46 |
| Indicator | CHOW | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.39 |
| Support Level | N/A | $2.15 |
| Resistance Level | N/A | $2.43 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 82.58 |
ChowChow Cloud International Holdings Ltd is providing one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey from consulting, deployment and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment (ii) professional IT services comprising of capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations including infrastructure applications.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.